To print: Select File and then Print from your browser's menu --------------------------------------------------------------------------------------- Title: FDA Advisory Committee Confirms Safety, Efficacy of Cardura (Doxazosin Mesylate) For High Blood Pressure/Benign Prostatic Hyperplasia URL: http://www.pslgroup.com/dg/1FC576.htm Doctor's Guide May 25, 2001
NEW YORK, NY -- May 25, 2001 -- Pfizer Inc said today that it is pleased that an FDA advisory panel affirmed that its alpha-blocker Cardura (doxazosin mesylate) is safe and effective as currently labeled for its indications of high blood pressure and benign prostatic hyperplasia. Pfizer said it will continue to work closely with the U.S. Food and Drug Administration and other regulatory agencies around the world as additional data from the ALLHAT trial becomes available to determine whether label additions are warranted. The advisory panel was reviewing data from a clinical trial sponsored by the National Institute of Health. In that trial, known as ALLHAT, preliminary results showed a lower incidence of congestive heart failure (CHF) in patients taking a diuretic, a commonly used treatment for CHF, for which Cardura is not indicated. In its presentation to the FDA panel, Pfizer said that a review of 316 Pfizer-sponsored clinical trials involving over 49,000 patients concluded that Cardura does not cause CHF. Further, neither Pfizer's own post-marketing database nor a review of 27 scientific articles that tracked nearly 6,000 patients showed evidence that Cardura is causally associated with CHF, heart attack or stroke. Cardura, which was approved in the United States in 1990, has accumulated over four billion patient days of experience.
SOURCE: Pfizer Inc
Related Links: Pfizer Inc and Cardura (doxazosin mesylate). --------------------------------------------------------------------------------------------- Copyright © 1999 P\S\L Consulting Group Inc. All rights reserved. Republication or redistribution of P\S\L content is expressly prohibited without the prior written consent of P\S\L. P\S\L shall not be liable for any errors, omissions or delays in this content or any other content on its sites, newsletters or other publications, nor for any decisions or actions taken in reliance on such content. --------------------------------------------------------------------------------------------- This news story was printed from *Doctor's Guide to the Internet* located at http://www.docguide.com --------------------------------------------------------------------------------------- Return to News Story Page This site is maintained by webmaster@pslgroup.com Please contact us with any comments, problems or bugs. All contents Copyright (c) 1998 P\S\L Consulting Group Inc. All rights reserved.